JP2012036194A - 持続放出製剤 - Google Patents
持続放出製剤 Download PDFInfo
- Publication number
- JP2012036194A JP2012036194A JP2011196884A JP2011196884A JP2012036194A JP 2012036194 A JP2012036194 A JP 2012036194A JP 2011196884 A JP2011196884 A JP 2011196884A JP 2011196884 A JP2011196884 A JP 2011196884A JP 2012036194 A JP2012036194 A JP 2012036194A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- protein
- pgg
- complex
- gallic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
【解決手段】タンパク質及び/又はペプチドを精製没食子酸エステルと共に複合化して製剤する。没食子酸エステルとしては、ペンタガロイルグルコース(PGG)や没食子酸エピガロカテキン(EGCG)が好ましく用いられる。タンパク質を精製没食子酸エステルと混合する工程、および沈殿物を単離する工程により製造する。
【選択図】なし
Description
実施例1は、ペプチドB−PGG塩(ペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)対PGGの1:1モル比)の製造の説明を提供する。PGG94mgをNaOH溶液2ml(0.10から0.20NのNaOH濃度)に溶解し、次にこれを0.2μmフィルターでろ過することによってPGGの原液を作製した。PGGの原液(1.56mL)に、水0.8mL中のペプチドB酢酸塩109.4mgの溶液を攪拌しながら連続的に添加し、沈殿物を形成させた。遠心分離によって沈殿物を回収した。
ペプチドA−PGGとタンニン酸の塩を、実施例1のペプチドB−PGGと同様にして作製した。ペプチドAは、アセチル Lys Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpgであった。
以下の表1及び2は、水中及びPBS中での、タンニン酸及びPGGとペプチドA(アセチル Lys Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)及びペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)の塩のペプチド含量及び溶解度を列挙する。データは、PGGペプチド塩がタンニン酸塩よりも高いペプチド含量を有することを示した。PGG沈殿物はタンニン酸塩よりも高いPBS溶解度を有する。
ペプチドB−PGG塩の収率、ペプチド含量及び溶解度への塩形成pH(すなわちNaOHの濃度レベル)の影響の試験を実施した。pH7.0、7.2、7.6及び8.6の4つのペプチドB−PGG塩を作製し、単離した。次に、水中及びPBS中でのこれらの溶解度、及びまたこれらのペプチド含量も測定した。これらの結果は、塩形成の間のpHが上昇すると共に水溶解度、塩形成の収率及びペプチド含量が上昇することを明らかにする(表3)。
この実施例は、ラットにおけるペプチドB/PGG及びペプチドB/タンニン酸塩の持続放出を述べる。ラット薬物動態(PK)試験を、TRIS緩衝液に懸濁したペプチドB/PGG塩及びペプチドB/タンニン酸塩;及び対照群としてペプチドB酢酸塩のPBS溶液の単回皮下注射(10mg/kg用量)によって実施した。PK結果は、pH7.0で作製したペプチドB/タンニン酸塩及びペプチドB/PGG塩に関して1週間の持続放出を示した。しかし、pH7.6及び8.6で作製したペプチドB/PGG塩は、pH7.0で作製した塩(2週間まで)に比べてより短い放出期間(約2−3日間)を示した。
ペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)のPGG塩の純粋なアノマー(β−PGG)及びアノマーの混合物(α+β−PGG)を、実施例1で述べたのと同様の方法によって作製した。これらの塩の水溶解度に有意差はなかった。水溶解度に基づき、これらの塩についてのインビボ持続放出期間は類似すると予想される。
以下の実施例は、持続放出に関する動物薬物動態(PK)試験において検討した、ペプチドとの塩を作製するためのEGCGの使用を述べる。EGCG184mgを0.2N NaOH 2ml中に溶解し、次にこれを0.2μmフィルターでろ過することによってEGCG(Sigma−Aldrich)の原液を作製した。EGCGの原液(1.4mL)に、水1.2mL中のペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)の酢酸塩138mgの溶液を攪拌しながら緩やかに添加した。生じた懸濁液を室温で約10−15分間攪拌した。遠心分離後、上清を傾瀉し、沈殿物を水1mLで洗った(遠心分離と上清の傾瀉ごとに3回ずつ)。沈殿物を真空下に約30−35℃で約20時間乾燥して、ペプチドB−EGCG塩218mg(88%)をオフホワイト色の粉末として得た。
Claims (10)
- タンパク質と精製没食子酸エステルの精製複合体を含む組成物であって、前記タンパク質が免疫グロブリン若しくはその一部又はキメラ抗体若しくはそのフラグメントである、前記組成物。
- 前記精製複合体が、ペプチドと没食子酸エステルの塩である、請求項1に記載の組成物。
- 前記精製没食子酸エステルが、ペンタガロイルグルコース(PGG)及び没食子酸エピガロカテキン(EGCG)から成る群より選択される、請求項1に記載の組成物。
- 前記精製没食子酸エステルがペンタガロイルグルコース(PGG)である、請求項3に記載の組成物。
- 前記精製没食子酸エステルが没食子酸エピガロカテキン(EGCG)である、請求項3に記載の組成物。
- 医薬適合性の担体、医薬適合性の賦形剤、またはそれらの両方をさらに含む、請求項1に記載の組成物。
- タンパク質を精製没食子酸エステルと混合する工程、および沈殿物を単離する工程を含み、前記タンパク質が免疫グロブリン若しくはその一部又はキメラ抗体若しくはそのフラグメントである、請求項1に記載の組成物を製造する方法。
- 前記精製没食子酸エステルが、ペンタガロイルグルコース(PGG)及び没食子酸エピガロカテキン(EGCG)から成る群より選択される、請求項7に記載の方法。
- 前記精製没食子酸エステルがペンタガロイルグルコース(PGG)である、請求項8に記載の方法。
- 前記精製没食子酸エステルが没食子酸エピガロカテキン(EGCG)である、請求項8に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56524704P | 2004-04-23 | 2004-04-23 | |
US60/565,247 | 2004-04-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Division JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2012036194A true JP2012036194A (ja) | 2012-02-23 |
Family
ID=34967842
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Expired - Fee Related JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
JP2011196884A Pending JP2012036194A (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
JP2011196883A Expired - Fee Related JP5829870B2 (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Expired - Fee Related JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011196883A Expired - Fee Related JP5829870B2 (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
Country Status (16)
Country | Link |
---|---|
US (2) | US7323169B2 (ja) |
EP (1) | EP1750683B1 (ja) |
JP (3) | JP5036533B2 (ja) |
KR (1) | KR101201638B1 (ja) |
CN (2) | CN1997356A (ja) |
AU (1) | AU2005237542B2 (ja) |
CA (1) | CA2563185C (ja) |
DK (1) | DK1750683T3 (ja) |
ES (1) | ES2400687T3 (ja) |
HK (2) | HK1103023A1 (ja) |
IL (1) | IL178596A (ja) |
PL (1) | PL1750683T3 (ja) |
PT (1) | PT1750683E (ja) |
SI (1) | SI1750683T1 (ja) |
WO (1) | WO2005105057A1 (ja) |
ZA (1) | ZA200609401B (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101201638B1 (ko) * | 2004-04-23 | 2012-11-15 | 암젠 인코포레이티드 | 서방성 제형 |
US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
US7252834B2 (en) * | 2005-04-25 | 2007-08-07 | Clemson University Research Foundation (Curf) | Elastin stabilization of connective tissue |
TWI364292B (en) * | 2005-06-30 | 2012-05-21 | Ipsen Pharma Sas | Glp-1 pharmaceutical compositions |
EP1993606A4 (en) * | 2006-02-15 | 2010-01-20 | Gammacan Ltd | VITILIGO PLASMA IMMUNOGLOBULINS FOR THE TREATMENT OF MELANOMA |
ES2446266T3 (es) * | 2006-07-21 | 2014-03-06 | Amgen Inc. | Método de detección y/o de medición de hepcidina en una muestra |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP2261254A3 (en) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
JP2011513220A (ja) * | 2008-02-21 | 2011-04-28 | ヴァトリックス・メディカル・インコーポレーテッド | デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置 |
US20100016833A1 (en) * | 2008-07-15 | 2010-01-21 | Ogle Matthew F | Devices for the Treatment of Vascular Aneurysm |
US20100119605A1 (en) * | 2008-11-12 | 2010-05-13 | Isenburg Jason C | Compositions for tissue stabilization |
US8444624B2 (en) | 2009-10-19 | 2013-05-21 | Vatrix Medical, Inc. | Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
US8911468B2 (en) | 2011-01-31 | 2014-12-16 | Vatrix Medical, Inc. | Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection |
EP2686340A2 (en) | 2011-03-16 | 2014-01-22 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
JP2014516695A (ja) | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
SG10201605027XA (en) | 2011-12-19 | 2016-08-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
JP6426107B2 (ja) | 2012-12-20 | 2018-11-21 | アムジエン・インコーポレーテツド | Apj受容体アゴニストおよびその使用 |
TW201446792A (zh) | 2013-03-12 | 2014-12-16 | Amgen Inc | Nav1.7之強效及選擇性抑制劑 |
EP4257152A3 (en) | 2014-06-10 | 2023-12-06 | Amgen Inc. | Apelin polypeptides |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
US11654114B2 (en) * | 2017-06-07 | 2023-05-23 | Egy-Nano Pharma, Lp | Oral prolonged drug delivery platforms |
KR20210080349A (ko) | 2018-08-03 | 2021-06-30 | 넥테로 메디칼, 인크. | 정제된 펜타갈로일 글루코스 및 전달용 장치 |
WO2020227437A1 (en) | 2019-05-06 | 2020-11-12 | Axial Biotherapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01121222A (ja) * | 1987-09-21 | 1989-05-12 | Bpd Biopharma Dev Ltd | 長時間にわたって薬剤の放出を維持・調節するための薬剤組成物 |
JPH06239716A (ja) * | 1993-02-17 | 1994-08-30 | Kanebo Ltd | ポリフェノール化合物含有組成物 |
JPH06345668A (ja) * | 1993-06-07 | 1994-12-20 | Shibayagi:Kk | 感染防御組成物およびその用途 |
JP2000080027A (ja) * | 1998-09-02 | 2000-03-21 | Taiyo Kagaku Co Ltd | 徐放性製剤 |
JP2002512182A (ja) * | 1998-04-20 | 2002-04-23 | ジェンザイム・コーポレーション | ポリマーブレンドから蛋白質のドラックデリバリー |
JP2002255811A (ja) * | 2001-02-28 | 2002-09-11 | Mg Seiyaku Kk | 蛋白質複合体形成剤 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
GB929405A (en) * | 1958-12-22 | 1963-06-19 | Upjohn Co | Processes for the encapsulation of particles |
CH498653A (fr) * | 1968-03-29 | 1970-11-15 | Kobayashi Takehiko | Procédé d'encapsulation de matières hydrophobes |
US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
CA2230494A1 (en) * | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics Inc. | Composition for sustained release of an agent |
AU4414497A (en) | 1996-09-13 | 1998-04-02 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6531154B1 (en) * | 1997-06-10 | 2003-03-11 | Brown University Research Foundation | Modulated release from biocompatible polymers |
AU8578498A (en) * | 1997-07-23 | 1999-02-16 | Perio Products Ltd. | Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity |
US5962522A (en) * | 1997-09-05 | 1999-10-05 | Avmax, Inc. | Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
US6180666B1 (en) | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6428818B1 (en) * | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
EP1225916A1 (en) | 1999-11-01 | 2002-07-31 | University Technology Corporation | Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |
US6713506B2 (en) * | 2000-10-11 | 2004-03-30 | University Of South Florida | Tea polyphenol esters and analogs thereof for cancer prevention and treatment |
WO2002067966A1 (en) * | 2001-02-22 | 2002-09-06 | Purdue Research Foundation | Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
US20040142048A1 (en) * | 2002-02-22 | 2004-07-22 | Morre Dorothy M. | Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer |
EP1524912A1 (en) * | 2002-07-26 | 2005-04-27 | DSM IP Assets B.V. | Compositions comprising lactoferrin |
US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7605120B2 (en) * | 2003-10-22 | 2009-10-20 | Amgen Inc. | Antagonists of the brandykinin B1 receptor |
KR101201638B1 (ko) * | 2004-04-23 | 2012-11-15 | 암젠 인코포레이티드 | 서방성 제형 |
-
2005
- 2005-04-25 KR KR1020067021346A patent/KR101201638B1/ko not_active IP Right Cessation
- 2005-04-25 AU AU2005237542A patent/AU2005237542B2/en not_active Ceased
- 2005-04-25 JP JP2007509735A patent/JP5036533B2/ja not_active Expired - Fee Related
- 2005-04-25 WO PCT/US2005/014254 patent/WO2005105057A1/en active Application Filing
- 2005-04-25 SI SI200531678T patent/SI1750683T1/sl unknown
- 2005-04-25 CN CNA2005800124592A patent/CN1997356A/zh active Pending
- 2005-04-25 US US11/114,473 patent/US7323169B2/en not_active Expired - Fee Related
- 2005-04-25 CA CA2563185A patent/CA2563185C/en not_active Expired - Fee Related
- 2005-04-25 EP EP05742315A patent/EP1750683B1/en active Active
- 2005-04-25 PL PL05742315T patent/PL1750683T3/pl unknown
- 2005-04-25 PT PT57423154T patent/PT1750683E/pt unknown
- 2005-04-25 ES ES05742315T patent/ES2400687T3/es active Active
- 2005-04-25 DK DK05742315.4T patent/DK1750683T3/da active
- 2005-04-25 CN CN201410023256.4A patent/CN103920162B/zh not_active Expired - Fee Related
-
2006
- 2006-10-15 IL IL178596A patent/IL178596A/en not_active IP Right Cessation
- 2006-11-13 ZA ZA200609401A patent/ZA200609401B/en unknown
-
2007
- 2007-08-13 HK HK07108780.0A patent/HK1103023A1/xx not_active IP Right Cessation
- 2007-08-30 US US11/847,984 patent/US7732399B2/en not_active Expired - Fee Related
-
2011
- 2011-09-09 JP JP2011196884A patent/JP2012036194A/ja active Pending
- 2011-09-09 JP JP2011196883A patent/JP5829870B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-16 HK HK15100510.4A patent/HK1200092A1/xx not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01121222A (ja) * | 1987-09-21 | 1989-05-12 | Bpd Biopharma Dev Ltd | 長時間にわたって薬剤の放出を維持・調節するための薬剤組成物 |
JPH06239716A (ja) * | 1993-02-17 | 1994-08-30 | Kanebo Ltd | ポリフェノール化合物含有組成物 |
JPH06345668A (ja) * | 1993-06-07 | 1994-12-20 | Shibayagi:Kk | 感染防御組成物およびその用途 |
JP2002512182A (ja) * | 1998-04-20 | 2002-04-23 | ジェンザイム・コーポレーション | ポリマーブレンドから蛋白質のドラックデリバリー |
JP2000080027A (ja) * | 1998-09-02 | 2000-03-21 | Taiyo Kagaku Co Ltd | 徐放性製剤 |
JP2002255811A (ja) * | 2001-02-28 | 2002-09-11 | Mg Seiyaku Kk | 蛋白質複合体形成剤 |
Also Published As
Publication number | Publication date |
---|---|
CN1997356A (zh) | 2007-07-11 |
AU2005237542A1 (en) | 2005-11-10 |
KR101201638B1 (ko) | 2012-11-15 |
CN103920162B (zh) | 2017-07-11 |
ES2400687T3 (es) | 2013-04-11 |
CA2563185C (en) | 2010-04-20 |
PL1750683T3 (pl) | 2013-05-31 |
WO2005105057A1 (en) | 2005-11-10 |
EP1750683A1 (en) | 2007-02-14 |
AU2005237542B2 (en) | 2009-12-17 |
IL178596A0 (en) | 2007-02-11 |
JP5036533B2 (ja) | 2012-09-26 |
US7732399B2 (en) | 2010-06-08 |
HK1103023A1 (en) | 2007-12-14 |
PT1750683E (pt) | 2013-01-25 |
JP5829870B2 (ja) | 2015-12-09 |
JP2012046520A (ja) | 2012-03-08 |
US20050271722A1 (en) | 2005-12-08 |
HK1200092A1 (en) | 2015-07-31 |
US7323169B2 (en) | 2008-01-29 |
EP1750683B1 (en) | 2013-01-09 |
KR20070026457A (ko) | 2007-03-08 |
JP2007534698A (ja) | 2007-11-29 |
ZA200609401B (en) | 2008-05-28 |
SI1750683T1 (sl) | 2013-04-30 |
DK1750683T3 (da) | 2013-04-15 |
US20070292506A1 (en) | 2007-12-20 |
CA2563185A1 (en) | 2005-11-10 |
IL178596A (en) | 2012-06-28 |
CN103920162A (zh) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5829870B2 (ja) | 持続放出製剤 | |
KR101337797B1 (ko) | 지속형 인간 성장 호르몬 결합체 액상 제제 | |
JP5774828B2 (ja) | ペプチドおよびタンパク質の薬学的因子の精製および安定化 | |
AU2003257156B2 (en) | Cell transport compositions and uses thereof | |
KR101340710B1 (ko) | 지속형 과립구 콜로니 자극인자 결합체의 액상 제제 | |
US20150290132A1 (en) | Cell Transport Compositions and Uses Thereof | |
PL215168B1 (pl) | Formulacja polipeptydowa | |
TW201004649A (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
KR20120043206A (ko) | 지속형 인터페론 알파 결합체의 액상 제제 | |
CA3042695A1 (en) | Melt processed viral nanoparticle constructs | |
JP2019511497A (ja) | エキセナチド類似体の持続放出コンジュゲート | |
KR102364521B1 (ko) | 알부민 및 폴리에틸렌글리콜을 포함하는 하이드로겔 및 그의 제조방법 | |
MXPA06012009A (es) | Formulaciones de liberacion prolongada | |
WO2023220690A1 (en) | Transient sirolimus with fasl microgels | |
JP6527697B2 (ja) | タンパク質を安定化させたゲル状製剤 | |
KR20220074813A (ko) | 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체 | |
US20180125791A1 (en) | Polymer nanocapsules for protein delivery | |
NZ786229A (en) | Extended release conjugates of exenatide analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130801 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140603 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140725 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150414 |